In Brief: Roche v. Organon Teknika
This article was originally published in The Gray Sheet
Executive SummaryRoche v. Organon Teknika: Roche files suit against Organon Teknika alleging that Teknika's NASBA gene amplification technology used in two HIV tests available in Europe infringes Roche's European patent for polymerase chain reaction amplification technology. The suit, filed in the District Court in The Hague, the Netherlands, seeks to prohibit Teknika from marketing the quantitative and qualitative HIV test kits in Europe, as well as any future assays using the NASBA technology. Teknika "has carefully studied and evaluated" Roche's PCR patent "and has concluded that [the patent] bears no relevance to the NASBA tests," the company says. Teknika, which has "a number" of patents for NASBA, is currently developing 10 additional assays based on the technology, including a test for tuberculosis...
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.